The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Investigation

• Publication date

  2007-01-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI28803PMID 17160137PMCID PMC1679964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A gene-expression signature to predict survival in breast cancer across independent data sets

  2007cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• Apoptosis Inhibition by the Human DEK Oncoprotein Involves Interference with p53 Functions

  2006influential reference
• A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.

  2005cited by this paper
• The growth arrest function of the human oncoprotein mouse double minute-2 is disabled by downstream mutation in cancer cells.

  2005cited by this paper
• The E2F transcriptional network: old acquaintances with new faces

  2005influential reference
• Endocrine therapy – current benefits and limitations

  2005cited by this paper
• Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy.

  2005cited by this paper
• Lifetime risks of common cancers among retinoblastoma survivors.

  2004influential reference
• Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

  2004influential reference
• RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult.

  2004cited by this paper
• pRb Inactivation in Mammary Cells Reveals Common Mechanisms for Tumor Initiation and Progression in Divergent Epithelia

  2004influential reference
• BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists

  2004cited by this paper
• Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents

  2004cited by this paper
• Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

  2004influential reference
• Apoptosis Resistance of MCF-7 Breast Carcinoma Cells to Ionizing Radiation Is Independent of p53 and Cell Cycle Control but Caused by the Lack of Caspase-3 and a Caffeine-Inhibitable Event

  2004cited by this paper
• E2F target genes: unraveling the biology.

  2004cited by this paper
• A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.

  2004cited by this paper
• DNA damage tumor suppressor genes and genomic instability.

  2004cited by this paper
• The estrogen receptor: a model for molecular medicine.

  2003cited by this paper
• Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.

  2003cited by this paper
• TP53 and breast cancer

  2003cited by this paper
• Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways.

  2003cited by this paper
• Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry

  2003cited by this paper
• Drosophila checkpoint kinase 2 couples centrosome function and spindle assembly to genomic integrity.

  2003cited by this paper
• Phosphorylation of Histone H2AX and Activation of Mre11, Rad50, and Nbs1 in Response to Replication-dependent DNA Double-strand Breaks Induced by Mammalian DNA Topoisomerase I Cleavage Complexes*

  2003cited by this paper
• Role of p53 in regulating constitutive and X-radiation-inducible CD95 expression and function in carcinoma cells.

  2003cited by this paper
• Cell Cycle-Dependent Expression of Phosphorylated Histone H2AX: Reduced Expression in Unirradiated but not X-Irradiated G1-Phase Cells

  2003cited by this paper
• Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.

  2003cited by this paper
• Overexpression of c-Myc Alters G1/S Arrest following Ionizing Radiation

  2002cited by this paper
• Truncating mutations of RB1CC1 in human breast cancer

  2002cited by this paper
• Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest

  2002cited by this paper
• Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

  2002cited by this paper
• Action Models for the Antitumor Drug Camptothecin: Formation of Alkali-labile Complex with DNA and Inhibition of Human DNA Topoisomerase I

  2002cited by this paper
• E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis

  2002influential reference
• Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action.

  2002influential reference
• Cell cycle regulators: role in etiology, prognosis and treatment in cancer.

  2002cited by this paper
• Direct coupling of the cell cycle and cell death machinery by E2F

  2002cited by this paper
• Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment

  2002cited by this paper
• The RB and p53 pathways in cancer.

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node

  2002cited by this paper
• RB activation defect in tumor cell lines

  2002cited by this paper
• Cyclin E and survival in patients with breast cancer.

  2002cited by this paper
• Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells

  2002cited by this paper
• DNA Damage Invokes Mismatch Repair-dependent Cyclin D1 Attenuation and Retinoblastoma Signaling Pathways to Inhibit CDK2*

  2002cited by this paper
• Neither p21WAF1 nor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resulting tetraploid cells.

  2001cited by this paper
• Pathways governing G1/S transition and their response to DNA damage

  2001influential reference
• Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

  2001cited by this paper
• Multifaceted Regulation of Cell Cycle Progression by Estrogen: Regulation of Cdk Inhibitors and Cdc25A Independent of Cyclin D1-Cdk4 Function

  2001cited by this paper
• Cyclin D1 Overexpression Induces Progestin Resistance in T-47D Breast Cancer Cells Despite p27Kip1 Association with Cyclin E-Cdk2*

  2001cited by this paper
• Retinoblastoma Tumor Suppressor Protein Signals through Inhibition of Cyclin-Dependent Kinase 2 Activity To Disrupt PCNA Function in S Phase

  2001cited by this paper
• Linking the Rb and polycomb pathways.

  2001influential reference
• To cycle or not to cycle: a critical decision in cancer

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Regulation of DNA replication fork progression through damaged DNA by the Mec1/Rad53 checkpoint

  2001cited by this paper
• Estrogen receptor: current understanding of its activation and modulation.

  2001cited by this paper
• Role for E2F in Control of Both DNA Replication and Mitotic Functions as Revealed from DNA Microarray Analysis

  2001influential reference
• Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.

  2000cited by this paper
• Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.

  2000cited by this paper
• RB-Dependent S-Phase Response to DNA Damage

  2000cited by this paper
• Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5′-Phosphorylated DNA Double-Strand Breaks by Replication Runoff

  2000cited by this paper
• Rb function in cell-cycle regulation and apoptosis

  2000cited by this paper
• A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence*

  2000cited by this paper
• The Efficiency and Fidelity of Translesion Synthesis past Cisplatin and Oxaliplatin GpG Adducts by Human DNA Polymerase β*

  2000cited by this paper
• Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization.

  2000cited by this paper
• Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain

  2000influential reference
• Tumor suppressor genes in breast cancer.

  1999cited by this paper
• Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.

  1999cited by this paper
• Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.

  1999cited by this paper
• The Expanding Role of Cell Cycle Regulators

  1998influential reference
• The J Domain of Simian Virus 40 Large T Antigen Is Required To Functionally Inactivate RB Family Proteins

  1998influential reference
• Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens.

  1998cited by this paper
• Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile.

  1998cited by this paper
• Mutant PCNA alleles are associated with cdc phenotypes and sensitivity to DNA damage in fission yeast

  1998cited by this paper
• pRB plays an essential role in cell cycle arrest induced by DNA damage.

  1998cited by this paper
• DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139*

  1998cited by this paper
• Second primary tumors in patients with retinoblastoma. A review of the literature.

  1997influential reference
• Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins.

  1997cited by this paper
• Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein

  1997cited by this paper
• Cyclins and Breast Cancer

  1996cited by this paper
• Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status.

  1996cited by this paper
• Oestrogen receptor: a stable phenotype in breast cancer.

  1996influential reference
• Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

  1995cited by this paper
• Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival.

  1995cited by this paper
• Genetic instability as a consequence of inappropriate entry into and Progression through S-phase

  1995cited by this paper
• Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes

  1995influential reference
• Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

  1995cited by this paper
• Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.

  1995cited by this paper
• Ethics of n-of-1 trials.

  1995cited by this paper
• E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product.

  1993influential reference
• Expression and amplification of cyclin genes in human breast cancer.

  1993cited by this paper
• The retinoblastoma protein as a transcriptional repressor.

  1993influential reference
• Specific enzymatic dephosphorylation of the retinoblastoma protein

  1993influential reference
• The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression.

  1992influential reference
• Molecular oncology

  1991cited by this paper
• Endocrine pharmacology of antiestrogens as antitumor agents.

  1990cited by this paper
• Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product.

  1989influential reference
• Inactivation of the retinoblastoma susceptibility gene in human breast cancers.

  1988cited by this paper
• Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product

  1988influential reference

• Genetic and epigenetic contribution to tamoxifen resistance in breast cancer, concepts to drive therapeutic strategies

  2025cites this paper
• Defining the Molecular Intricacies of Human Papillomavirus-Associated Tonsillar Carcinoma

  2025cites this paper
• NRF-Mediated Autophagy and UPR: Exploring New Avenues to Overcome Cancer Chemo-Resistance.

  2024cites this paper
• p16 Immunohistochemical Patterns in Triple-Negative Breast Cancer: Clinical and Genomic Similarities of the p16 Diffuse Pattern to pRB Deficiency

  2024cites this paper
• Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer

  2024cites this paper
• Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.

  2023cites this paper
• Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers.

  2023cites this paper
• Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeutics.

  2023cites this paper
• Moving the Needle Forward in Genomically-Guided Precision Radiation Treatment

  2023cites this paper
• CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas

  2023cites this paper
• Determinants of response to CDK4/6 inhibitors in the real-world setting

  2023cites this paper
• Radiosensitization of Breast Cancer Cells with a 2-Methoxyestradiol Analogue Affects DNA Damage and Repair Signaling In Vitro

  2023cites this paper
• RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis

  2023cites this paper
• Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition

  2022cites this paper
• ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers

  2022cites this paper
• Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer

  2022cites this paper
• Novel insights into RB1 mutation.

  2022cites this paper
• CCR-21-3189 3618..3629

  2022cites this paper
• Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition

  2022cites this paper
• Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer

  2021cites this paper
• Identification of novel RB1 genetic variants in Retinoblastoma patients and their impact on clinical outcome

  2021cites this paper
• Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

  2021cites this paper
• RB/E2F1 as a master regulator of cancer cell metabolism in advanced disease.

  2021cites this paper
• Relevance of pRB Loss in Human Malignancies

  2021cites this paper
• Statins and endocrine resistance in breast cancer

  2021cites this paper
• Strategic Developments & Future Perspective on Gene therapy of Breast Cancer: Role of mTOR and Brk/ PTK6 as Molecular Targets.

  2020cites this paper
• Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities

  2020cites this paper
• Silencing of the Long Noncoding RNA MYCNOS1 Suppresses Activity of MYCN-Amplified Retinoblastoma Without RB1 Mutation

  2020cites this paper
• BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

  2020cites this paper
• Cell Cycle, DNA Replication, Centrosomes, Centrioles and Cell Division

  2020cites this paper
• Cyclins E1 and E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.

  2020cites this paper
• Tumor Milieu Controlled by RB Tumor Suppressor

  2020cites this paper
• Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.

  2019cites this paper
• PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement

  2019cites this paper
• Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer

  2019cites this paper
• Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis

  2019influential citation
• Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes

  2019cites this paper
• Translating RB1 predictive value in clinical cancer therapy: Are we there yet?

  2019cites this paper
• Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

  2019cites this paper
• Cyclin D1 is Associated with Radiosensitivity of Triple-Negative Breast Cancer Cells to Proton Beam Irradiation

  2019cites this paper
• A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients

  2018cites this paper
• Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer.

  2018cites this paper
• Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer

  2018cites this paper
• Non-canonical functions of the RB protein in cancer

  2018cites this paper
• Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer

  2018cites this paper
• A genome-inspired, reverse selection approach to aptamer discovery.

  2018cites this paper
• Prognostic Values of CCNE1 Amplification and Overexpression in Cancer Patients: A Systematic Review and Meta-analysis

  2018cites this paper
• The RB–IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity

  2017cites this paper
• Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.

  2017cites this paper
• Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells

  2017cites this paper
• MicroRNA-140 mediates RB tumor suppressor function to control stem cell-like activity through interleukin-6

  2017cites this paper
• G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer

  2017cites this paper
• TARGETING AUTOPHAGY TO IMPROVE EFFICACY OF CDK4/6 INHIBITION IN BREAST CANCER

  2017cites this paper
• CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib

  2017cites this paper
• Targeting the CDK4/6 Pathway in Breast Cancer

  2017cites this paper
• Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair

  2017cites this paper
• Progress with palbociclib in breast cancer: latest evidence and clinical considerations

  2017cites this paper
• Intersection of retinoblastoma tumor suppressor function, stem cells, metabolism, and inflammation

  2017cites this paper
• A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer

  2017cites this paper
• CDK4/6 inhibitors in HER2-positive breast cancer.

  2017cites this paper
• Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer

  2017cites this paper
• UNIVERSITY OF NAPLES “FEDERICO II” DOCTORATE MOLECULAR MEDICINE AND MEDICAL BIOTECHNOLOGY XXIX CYCLE TARGETING SUBTYPES OF BREAST CANCER CELLS WITH PALBOCICLIB, A CYCLIN-DEPENDENT KINASE INHIBITOR

  2017cites this paper
• Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells

  2017cites this paper
• Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value

  2017cites this paper
• Advances in systemic therapy for metastatic breast cancer: future perspectives

  2017cites this paper
• Intersection of retinoblastoma tumor suppressor function, stem cells, metabolism, and inflammation

  2017cites this paper
• Identifying Patterns of Cancer Disease Mechanisms by Mining Alternative Representations of Genomic Alterations

  2017cites this paper
• Clinical Significance of Genes in the NeoTYPE Brain Tumor Profile

  2017cites this paper
• The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment

  2016cites this paper
• Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel

  2016cites this paper
• Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.

  2016cites this paper
• High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer

  2016cites this paper
• CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update

  2016cites this paper
• Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer

  2016cites this paper
• Retinoblastoma tumor suppressor functions shared by stem cell and cancer cell strategies.

  2016cites this paper
• RB1: a prototype tumor suppressor and an enigma

  2016cites this paper
• What to expect from high throughput genomics in metastatic breast cancers?

  2015cites this paper
• SYNTHETIC LETHALITY OF CDK INHIBITION AND DOXORUBICIN IN TRIPLE-NEGATIVE BREAST CANCER REQUIRES P53 INACTIVATION

  2015cites this paper
• RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy

  2015cites this paper
• RbAp48 Is Critical for the Proliferation of Hypopharyngeal Carcinoma

  2015cites this paper
• Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

  2015cites this paper
• Therapeutic targeting of replicative immortality

  2015cites this paper
• Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors

  2015cites this paper
• A Novel Retinoblastoma Protein (RB) E3 Ubiquitin Ligase (NRBE3) Promotes RB Degradation and Is Transcriptionally Regulated by E2F1 Transcription Factor*

  2015cites this paper
• RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer

  2015cites this paper
• Personalized Therapy of Cancer

  2015cites this paper
• Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

  2015cites this paper
• The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients

  2015cites this paper
• An overview of new biomolecular pathways in pathogen-related cancers.

  2015cites this paper
• RB 1 dual role in proliferation and apoptosis : Cell fate control and implications for cancer therapy

  2015cites this paper
• Regulation of Mitotic Cytoskeleton Dynamics and Cytokinesis by Integrin-Linked Kinase in Retinoblastoma Cells

  2014cites this paper
• The role of the proline rich homeodomain in the regulation of proliferation, survival and migration of breast cells

  2014cites this paper
• MicroRNAs as regulatory elements in triple negative breast cancer.

  2014cites this paper
• MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer

  2014cites this paper
• Adjusting for misclassification in a stratified biomarker clinical trial

  2014cites this paper
• The other side of the coin: The tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND–CDK4/6–RB axis

  2014cites this paper
• Squamous cell oesophageal cancer in retinoblastoma survivor: does germinal RB1 mutation influence chemo- and radiosensitivity?

  2014cites this paper
• Personalized Cancer Therapy

  2014cites this paper
• P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas

  2014cites this paper
• Cyclin Kinase Inhibitors in Breast Cancer: From Bench to Bedside

  2014cites this paper